Lipid Metabolism Practice Questions

Q: Glycolipids are mostly found in which of the following structures?

Brain. **Explanation:** **Correct Answer: B. Brain** Glycolipids (lipids with attached carbohydrates) are essential components of cell membranes, but they are found in the highest concentration within the **nervous system**, particularly the **brain** [1]. The primary reason for this localization is the abundance of **myelin** and specialized neuronal membranes. The most common glycolipids in the brain are **glycosphingolipids** (cerebrosides and gangliosides). * **Cerebrosides** (e.g., Galactocerebroside) are the major glycolipids in the myelin sheath, providing electrical insulation for axons [3]. * **Gangliosides** are concentrated in the gray matter (neuronal cell bodies), where they act as receptors for neurotransmitters and play a role in cell-to-cell recognition and signaling. **Why other options are incorrect:** * **A. Liver:** While the liver is the primary site for lipid metabolism and synthesis, it does not store or utilize glycolipids as a structural hallmark compared to the brain. * **C. Spinal cord:** Although the spinal cord contains myelin, the total concentration and diversity of complex glycolipids (especially gangliosides) are significantly higher in the brain's cortical and subcortical structures. * **D. Testis:** The testis contains specialized lipids for steroidogenesis, but glycolipids are not a predominant feature of its tissue architecture. **High-Yield NEET-PG Pearls:** 1. **Galactocerebroside** is the characteristic glycolipid of the myelin sheath (Brain) [2]. 2. **Glucocerebroside** is more common in non-neural tissues. 3. **Clinical Correlation:** Deficiencies in lysosomal enzymes that break down these glycolipids lead to **Sphingolipidoses** (e.g., Gaucher’s disease, Tay-Sachs disease, and Krabbe’s disease), which often present with severe neurological deterioration due to the brain's high glycolipid content [2].

Q: Which chemical mediator is an arachidonic acid metabolite produced by the cyclooxygenase pathway?

Prostaglandin H2 (PGH2). The metabolism of **Arachidonic Acid (AA)**, a 20-carbon polyunsaturated fatty acid derived from membrane phospholipids, occurs via two primary enzymatic pathways: the **Cyclooxygenase (COX)** pathway and the **Lipoxygenase (LOX)** pathway [3]. **Why Prostaglandin H2 (PGH2) is Correct:** The COX pathway (involving COX-1 and COX-2 enzymes) converts arachidonic acid into unstable intermediate endoperoxides, specifically **Prostaglandin G2 (PGG2)** and subsequently **Prostaglandin H2 (PGH2)** [1]. PGH2 serves as the common precursor for the synthesis of various biologically active prostanoids, including Prostaglandins (PGE2, PGD2, PGF2α), Prostacyclin (PGI2), and Thromboxane A2 (TXA2) [1]. **Analysis of Incorrect Options:** * **Leukotriene A4 (LTA4) & Leukotriene B4 (LTB4):** These are products of the **5-Lipoxygenase (5-LOX)** pathway. LTA4 is the initial unstable intermediate, which is then converted into LTB4 (a potent chemotactic agent) or the cysteinyl leukotrienes (LTC4, LTD4, LTE4). * **5-Hydroxyeicosatetraenoic acid (5-HETE):** This is also a product of the **5-LOX** pathway. It is a precursor to leukotrienes and acts as a potent chemoattractant for neutrophils. **High-Yield Clinical Pearls for NEET-PG:** * **Pharmacological Inhibition:** Aspirin and NSAIDs irreversibly or reversibly inhibit the **COX pathway**, thereby blocking the production of PGH2 and its derivatives [2]. * **Corticosteroids:** These inhibit **Phospholipase A2**, preventing the release of arachidonic acid from the cell membrane, thus blocking *both* the COX and LOX pathways. * **Zileuton:** A specific inhibitor of the 5-LOX pathway, used in asthma management. * **Prostacyclin (PGI2) vs. Thromboxane (TXA2):** PGI2 (from vascular endothelium) causes vasodilation and inhibits platelet aggregation, while TXA2 (from platelets) causes vasoconstriction and promotes aggregation.

Q: What are the characteristic findings in familial hypercholesterolemia?

total cholesterol. **Explanation:** **Familial Hypercholesterolemia (FH)** is an autosomal dominant disorder primarily caused by mutations in the **LDL receptor gene**. This defect leads to the inability of the liver and peripheral tissues to clear LDL-cholesterol from the blood. **Why Total Cholesterol is the Correct Answer:** In FH, the hallmark laboratory finding is a massive elevation in **Total Cholesterol** (often >300 mg/dL in heterozygotes and >600 mg/dL in homozygotes). Since LDL is the primary carrier of cholesterol in the blood, the failure of LDL receptors causes a secondary, dramatic rise in total serum cholesterol levels. This leads to premature atherosclerosis and characteristic clinical features like **Xanthomas** (tendon) and **Xanthelasmas**. **Analysis of Incorrect Options:** * **Options A & D (HDL):** High-Density Lipoprotein (HDL) is known as "good cholesterol." In FH, HDL levels are typically normal or slightly decreased; they are never the characteristic elevated marker for this condition. * **Option B (LDL):** While LDL levels are indeed elevated in FH, the question asks for the characteristic finding often used in clinical screening and classification (Fredrickson Type IIa). In the context of this specific question and standard NEET-PG patterns, "Total Cholesterol" is the broader clinical hallmark representing the overall lipid burden. **NEET-PG High-Yield Pearls:** * **Inheritance:** Autosomal Dominant. * **Defect:** Most commonly the **LDL Receptor**; others include ApoB-100 or PCSK9 mutations. * **Clinical Signs:** Tendon xanthomas (especially the **Achilles tendon**) and Corneal arcus at a young age. * **Fredrickson Classification:** FH is classified as **Type IIa** (elevated LDL and Total Cholesterol). * **Treatment:** Statins are the first line; PCSK9 inhibitors (evolocumab) are used for refractory cases.

Q: Which of the following enzymes is the most important enzyme for regulating lipogenesis?

Acetyl-CoA carboxylase. **Explanation:** **Acetyl-CoA Carboxylase (ACC)** is the correct answer because it catalyzes the **rate-limiting and committed step** in fatty acid synthesis (lipogenesis). This enzyme converts Acetyl-CoA to Malonyl-CoA using biotin as a cofactor, ATP, and CO₂. Its regulatory importance stems from two mechanisms: 1. **Allosteric Regulation:** It is activated by Citrate (signaling high energy) and inhibited by Palmitoyl-CoA (feedback inhibition). 2. **Hormonal Regulation:** It is activated by Insulin (via dephosphorylation) and inhibited by Glucagon/Epinephrine (via phosphorylation by AMPK). Furthermore, Malonyl-CoA produced by ACC inhibits *Carnitine Palmitoyltransferase-I (CPT-I)*, preventing a futile cycle by stopping fatty acid oxidation while synthesis is active. **Why other options are incorrect:** * **Hydratase, Enoyl reductase, and Acetyl transacetylase** are all components of the **Fatty Acid Synthase (FAS) multienzyme complex**. While essential for the elongation of the fatty acid chain, they are not regulatory or rate-limiting steps. They function downstream of ACC once the committed Malonyl-CoA is already formed. **High-Yield Clinical Pearls for NEET-PG:** * **Cofactors for ACC:** Remember **ABC** (ATP, Biotin, and CO₂). * **Location:** Lipogenesis occurs in the **cytosol**, whereas beta-oxidation occurs in the mitochondria. * **Citrate Shuttle:** Acetyl-CoA leaves the mitochondria in the form of Citrate to participate in lipogenesis. * **Metformin Link:** Metformin activates AMPK, which phosphorylates and inhibits ACC, contributing to its lipid-lowering effects.

Q: Which enzyme is the rate-limiting step in testosterone synthesis?

20,22-desmolase. **Explanation:** **Correct Answer: B. 20,22-desmolase** The synthesis of all steroid hormones, including testosterone, begins with cholesterol. The conversion of **cholesterol to pregnenolone** is the first and **rate-limiting step** in steroidogenesis. This reaction is catalyzed by the enzyme **20,22-desmolase** (also known as Cholesterol Side-Chain Cleavage enzyme or **CYP11A1**), located on the inner mitochondrial membrane. In the testes, this step is primarily regulated by **Luteinizing Hormone (LH)**, which increases the transport of cholesterol into the mitochondria via the **StAR (Steroidogenic Acute Regulatory) protein**. **Analysis of Incorrect Options:** * **A. 17,20 lyase:** This enzyme converts 17-hydroxypregnenolone to dehydroepiandrosterone (DHEA). While essential for the androgenic pathway, it is not the rate-limiting step. * **C. 3-beta-HSD:** This enzyme converts pregnenolone to progesterone (and DHEA to androstenedione). It is a crucial step in the synthesis of all classes of steroid hormones but is not the bottleneck of the pathway. * **D. 17-hydroxylase:** This enzyme converts pregnenolone to 17-hydroxypregnenolone. While it "shunts" precursors toward the sex steroid/cortisol pathways (away from aldosterone), it is not the overall rate-limiting enzyme. **High-Yield Clinical Pearls for NEET-PG:** * **StAR Protein:** The actual "bottleneck" at the molecular level is the transport of cholesterol into the mitochondria by the StAR protein. * **Location:** 20,22-desmolase is found in the **Leydig cells** of the testes. * **Final Step:** The final step in testosterone synthesis is the conversion of androstenedione to testosterone by **17β-hydroxysteroid dehydrogenase (17β-HSD)**. * **Potency:** Testosterone is converted to the more potent **Dihydrotestosterone (DHT)** by the enzyme **5-alpha-reductase** in peripheral tissues.

Q: Increased risk of coronary heart disease is seen in which type of hyperlipidemia?

Type II hyperlipidemia. The risk of **Coronary Heart Disease (CHD)** is most strongly associated with elevated levels of **Low-Density Lipoprotein (LDL)**, which is the primary characteristic of **Type II Hyperlipidemia** (Fredrickson Classification) [1]. 1. **Why Type II is Correct:** * **Type IIa:** Characterized by isolated elevation of LDL due to a deficiency in LDL receptors [1]. * **Type IIb:** Characterized by elevations in both LDL and Very Low-Density Lipoprotein (VLDL). Since LDL is highly atherogenic, it undergoes oxidation within the arterial wall, leading to foam cell formation and plaque buildup. Therefore, Type II carries the highest risk for premature atherosclerosis and myocardial infarction [1]. 2. **Why Other Options are Incorrect:** * **Type I (Hyperchylomicronemia):** Involves an increase in Chylomicrons due to Lipoprotein Lipase (LPL) deficiency. While it causes extremely high triglycerides, it is **not** associated with increased CHD risk. The primary clinical risk here is **acute pancreatitis**. * **Type IV (Hypertriglyceridemia):** Involves elevated VLDL. While high triglycerides are a minor risk factor, they are not as strongly or directly linked to CHD as the LDL elevations seen in Type II. * **Type V:** Involves elevations in both Chylomicrons and VLDL. Like Type I, the predominant clinical concern is pancreatitis rather than accelerated atherosclerosis. **High-Yield Clinical Pearls for NEET-PG:** * **Type IIa** is associated with **Tendon Xanthomas** (especially the Achilles tendon) and Xanthelasma. * **Type III (Dysbetalipoproteinemia)** is associated with **Palmar Xanthomas** and also carries an increased risk of CHD and peripheral vascular disease. * **Mnemonic for Fredrickson:** "1-2-3-4-5" corresponds to "C-L-B-V-M" (Chylomicrons, LDL, Broad-beta, VLDL, Mixed). * **Most common type:** Type IV is the most common in the general population, but Type II is the most significant for CHD [2].

Q: Which of the following enzymes is absent in Wolman's disease?

Acid lipase. **Explanation:** **Wolman’s Disease** is a rare, autosomal recessive lysosomal storage disorder characterized by a severe deficiency of the enzyme **Lysosomal Acid Lipase (LAL)**. 1. **Why Acid Lipase is correct:** Under normal physiological conditions, LAL is responsible for the hydrolysis of cholesteryl esters and triglycerides (delivered via LDL) into free cholesterol and free fatty acids within the lysosomes. In Wolman’s disease, the absence of this enzyme leads to the massive accumulation of these lipids in various organs, particularly the liver, spleen, and adrenal glands. 2. **Why other options are incorrect:** * **Cholesterol ester hydrolase:** While LAL functions as a hydrolase for cholesterol esters, the specific clinical name for the deficient enzyme in this pathology is Acid Lipase. * **Acid hydrolase:** This is a broad category of enzymes found in lysosomes (including proteases, nucleases, etc.). It is not a specific enzyme name. * **Acyl-CoA carnitine:** This refers to the carnitine shuttle system (CPT-1/CPT-2) involved in the transport of long-chain fatty acids into the mitochondria for beta-oxidation, unrelated to lysosomal storage. **High-Yield Clinical Pearls for NEET-PG:** * **Pathognomonic Sign:** Bilateral **adrenal calcification** is a classic radiological finding in Wolman’s disease. * **Clinical Presentation:** Infants typically present with hepatosplenomegaly, steatorrhea, and failure to thrive. It is usually fatal within the first year of life. * **Related Condition:** **Cholesteryl Ester Storage Disease (CESD)** is a milder, later-onset form of LAL deficiency where some residual enzyme activity remains. * **Gene Mutation:** Mutations occur in the *LIPA* gene located on chromosome 10.

Question 1

Glycolipids are mostly found in which of the following structures?

Accepted Answer

Brain

Answer

Liver

Answer

Spinal cord

Answer

Testis

Question 2

Which chemical mediator is an arachidonic acid metabolite produced by the cyclooxygenase pathway?

Accepted Answer

Prostaglandin H2 (PGH2)

Answer

Leukotriene A4 (LTA4)

Answer

Leukotriene B4 (LTB4)

Answer

5-Hydroxyeicosatetraenoic acid (5-HETE)

Question 3

What are the characteristic findings in familial hypercholesterolemia?

Accepted Answer

total cholesterol

Answer

HDL

Answer

LDL

Answer

HDL

Question 4

In chronic diabetics, why are the values of triglycerides (TG) and very-low-density lipoprotein (VLDL) elevated?

Accepted Answer

Increased activity of hormone-sensitive lipase and decreased lipoprotein lipase activity

Answer

Increased activity of hepatic lipase

Answer

Increased peripheral function of LDL receptors

Answer

Increased activity of lipoprotein lipase and decreased activity of hormone-sensitive lipase

Question 5

Which of the following enzymes is the most important enzyme for regulating lipogenesis?

Accepted Answer

Acetyl-CoA carboxylase

Answer

Hydratase

Answer

Enoyl reductase

Answer

Acetyl transacetylase

Question 6

Which enzyme is the rate-limiting step in testosterone synthesis?

Accepted Answer

20,22-desmolase

Answer

17,20 lyase

Answer

3-beta-hydroxysteroid dehydrogenase (3-beta-HSD)

Answer

17-hydroxylase

Question 7

Increased risk of coronary heart disease is seen in which type of hyperlipidemia?

Accepted Answer

Type II hyperlipidemia

Answer

Type I hyperlipidemia

Answer

Type IV hyperlipidemia

Answer

Type V hyperlipidemia

Question 8

A premature infant, when born, had low Apgar scores and was experiencing difficulty breathing. The NICU physician administered a lipid mixture that significantly reduced the respiratory distress. Besides proteins, what is a key component of this mixture?

Accepted Answer

Phosphatidylcholine

Answer

Sphingomyelin

Answer

A mixture of gangliosides

Answer

Triacylglycerol

Question 9

What is true about the lecithin-sphingomyelin ratio in amniotic fluid?

Accepted Answer

Concentration of lecithin and sphingomyelin in amniotic fluid are equal before 34 weeks.

Answer

Concentration of lecithin is greater than sphingomyelin in amniotic fluid before 34 weeks.

Answer

After 32 to 34 weeks, the concentration of sphingomyelin relative to lecithin begins to rise.

Answer

There is an increased risk of Respiratory Distress Syndrome if the L/S ratio is less than 2.

Question 10

Which of the following enzymes is absent in Wolman's disease?

Accepted Answer

Acid lipase

Answer

Cholesterol ester hydrolase

Answer

Acid hydrolase

Answer

Acyl-CoA carnitine

Lipid Metabolism — MCQs

Lipid Metabolism — MCQs

On this page

Practice by Chapter

Want unlimited practice?